US22053A1079 - Common Stock
CORTEXYME INC
NASDAQ:CRTX (7/29/2022, 7:00:01 PM)
After market: 1.99 +0.04 (+2.05%)1.95
+0.05 (+2.63%)
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The firm's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.
CORTEXYME INC
269 East Grand Ave
South San Francisco CALIFORNIA 94080
P: 14159105717.0
CEO: Casey C. Lynch
Employees: 55
Website: https://www.cortexyme.com/
Here you can normally see the latest stock twits on CRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: